CLINICAL TRIALS PROFILE FOR HERCEPTIN

Biosimilar Clinical Trials for HERCEPTIN

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02149524 ↗	A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer	Completed	Samsung Bioepis Co., Ltd.	Phase 3	2014-04-01	A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting
NCT03013504 ↗	A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients	Active, not recruiting	Prestige Biopharma Limited	Phase 3	2018-01-01	In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
NCT03013504 ↗	A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients	Active, not recruiting	Prestige Biopharma Ltd	Phase 3	2018-01-01	In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
NCT03013504 ↗	A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients	Active, not recruiting	Prestige Biopharma Pte Ltd	Phase 3	2018-01-01	In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
NCT03084237 ↗	Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer	Active, not recruiting	Shanghai Henlius Biotech	Phase 3	2016-11-01	This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent or previously untreated metastatic breast cancer.
NCT03425656 ↗	Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer	Completed	AryoGen Pharmed Co.	Phase 3	2016-07-09	This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab in comparison to Herceptin® (Genentech/Roche) in patients with Human Epidermal Growth Factor Receptor 2-Positive breast cancer. The main objective is to verify the non-inferiority of AryoTrust (Aryogen trastuzumab) vs. Herceptin® (Genentech/Roche trastuzumab), both given concomitantly with docetaxel after doxorubicin plus cyclophosphamide in the neoadjuvant setting according to pathological complete response (pCR) as primary objective and objective response (cOR), clinical complete response (cCR), clinical partial response (cPR), clinical stable disease (cSD), clinical progressive disease (cPD), breast conservation rate as Secondary objectives of this study. Evaluating the safety and immunogenicity of AryoTrust vs. Herceptin®, are also the other secondary outcomes. This study has two arms and 108 subjects will participate with a 1:1 allocation and receive mentioned treatment randomly.
NCT03989037 ↗	A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer	Unknown status	Fudan University	Phase 3	2019-06-30	The study will compare PK, efficacy, safety, and immunogenicity of SIBP-01 (Trastuzumab Biosimilar) in combination with Docetaxel and Carboplatin versus Herceptin® (CN-Trastuzumab) approved in the CN in combination with Docetaxel and Carboplatin in patients with operable HER2 positive, with early or locally advanced HER2-positive breast cancer. The hypothesis to be tested in this study is the tpCR of patients with Cycle 6 of SIBP-01 is similar to CN-approved trastuzumab, using a 90% bilateral confidence interval between 0.74 and 1.5.

All Clinical Trials for HERCEPTIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003440 ↗	Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic	Completed	National Cancer Institute (NCI)	Phase 3	1998-07-01	This randomized phase III studies how well two different regimens of paclitaxel with or without trastuzumab works in treating patients with or without HER-2/Neu breast cancer that is inoperable, recurrent, or metastatic. Drugs used in chemotherapy, such as paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known what regimen of paclitaxel is more effective with or without trastuzumab in treating patients with breast cancer.
NCT00003539 ↗	Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1998-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody therapy in treating women with recurrent or metastatic breast cancer.
NCT00003539 ↗	Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1998-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody therapy in treating women with recurrent or metastatic breast cancer.
NCT00003612 ↗	Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2.
NCT00003612 ↗	Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 2	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2.
NCT00003797 ↗	Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas	Unknown status	National Cancer Institute (NCI)	Phase 2	1999-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and trastuzumab in treating patients who have metastatic cancer of the pancreas that overexpresses HER2/neu.
NCT00003797 ↗	Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas	Unknown status	Brown University	Phase 2	1999-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and trastuzumab in treating patients who have metastatic cancer of the pancreas that overexpresses HER2/neu.

Clinical Trial Conditions for HERCEPTIN

Condition Name

Condition Name for HERCEPTIN
Intervention	Trials
Breast Cancer	272
HER2-positive Breast Cancer	44
Breast Neoplasms	39
Metastatic Breast Cancer	39

Condition MeSH

Condition MeSH for HERCEPTIN
Intervention	Trials
Breast Neoplasms	444
Stomach Neoplasms	34
Neoplasm Metastasis	31
Carcinoma	24

Clinical Trial Locations for HERCEPTIN

Trials by Country

Trials by Country for HERCEPTIN
Location	Trials
Italy	313
Spain	241
Brazil	96
Germany	92
Russian Federation	86

Trials by US State

Trials by US State for HERCEPTIN
Location	Trials
California	100
Texas	98
New York	91
Massachusetts	86
Florida	85

Clinical Trial Progress for HERCEPTIN

Clinical Trial Phase

Clinical Trial Phase for HERCEPTIN
Clinical Trial Phase	Trials
PHASE2	2
Phase 4	7
Phase 3	95

Clinical Trial Status

Clinical Trial Status for HERCEPTIN
Clinical Trial Phase	Trials
Completed	281
Recruiting	62
Active, not recruiting	61

Clinical Trial Sponsors for HERCEPTIN

Sponsor Name

Sponsor Name for HERCEPTIN
Sponsor	Trials
National Cancer Institute (NCI)	110
Hoffmann-La Roche	83
Genentech, Inc.	49

Sponsor Type

Sponsor Type for HERCEPTIN
Sponsor	Trials
Other	523
Industry	423
NIH	111

Herceptin (Trastuzumab): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 5, 2026

Executive Summary

Herceptin (trastuzumab), developed by Genentech (a Roche subsidiary), revolutionized HER2-positive breast cancer treatment since its approval in 1998. As a monoclonal antibody targeting the HER2 receptor, Herceptin remains a cornerstone in oncology. This report offers a comprehensive analysis of recent clinical trial developments, market dynamics, and future outlooks. Key insights highlight ongoing research into expanded indications, combination therapies, biosafety enhancements, and evolving market competition, providing strategic intelligence for stakeholders.

---

Introduction

Herceptin’s success is driven by its targeted mechanism against HER2-overexpressing tumors, accounting for approximately 15-20% of breast cancers globally. The drug's lifecycle encompasses multiple indications, including metastatic breast cancer, early-stage adjuvant therapy, gastric cancer, and investigational uses in other tumors.

The current landscape involves significant advancements with biosimilars, novel antibody-drug conjugates (ADCs), and combination regimens. Understanding these dynamics is crucial for pharmaceutical companies, healthcare providers, and investors.

---

Clinical Trials Update

Recent and Ongoing Clinical Trial Landscape

Trial Name	Phase	Population	Intervention	Endpoint	Status	Key Objectives
HER2CLIMB	Phase III	Metastatic HER2+ breast cancer	Tucatinib + trastuzumab + capecitabine	PFS, OS	Completed (2020)	Evaluate efficacy of combining tucatinib with Herceptin
HERA	Phase III	Early-stage HER2+ breast cancer	Trastuzumab (1, 2, or 3 years)	DFS	Completed	Assess optimal duration of adjuvant trastuzumab
HERMITAGE	Phase II	HER2-positive gastric cancer	Trastuzumab + chemotherapy	ORR, PFS	Ongoing	Investigate efficacy in gastric adenocarcinoma
NCT04314708	Phase I/II	HER2-low breast cancer	Trastuzumab deruxtecan	ORR	Active, recruiting	Expand indication to HER2-low subtypes alongside Herceptin

Key Recent Clinical Trial Findings

• Tucatinib + Herceptin: Demonstrated doubling of median PFS (7.8 vs. 5.4 months) in metastatic HER2+ breast cancer (HER2CLIMB study). This combination received FDA approval in 2020, underscoring reliance on combination strategies to extend survival.

• HER2-low Expression Exploration: Trials with trastuzumab deruxtecan (ADC) have shown activity in HER2-low breast cancers—an area where Herceptin’s efficacy remains uncertain—prompting debates over potential shifts in indication strategies.

• Adjuvant Therapy Duration: The HERA trial established 1-year trastuzumab therapy as standard but also explored extensions up to 2 years; current discussions consider tailoring duration based on risk stratification.

Emerging Innovations in Clinical Development

• Biosimilar Trials: Multiple phase III biosimilar studies (e.g., PF-05280014, Batocustumab) aim at increasing access and reducing costs, with several biosimilars approved in 2022 across various regions.
• Antibody-Drug Conjugates (ADCs): Trials like DESTINY-Breast04 evaluate trastuzumab deruxtecan in HER2-low populations, potentially expanding Herceptin's competitive landscape.

Future Clinical Directions

• Trials focusing on combination immunotherapy with checkpoint inhibitors (e.g., pembrolizumab) are under active investigation.
• Investigations into minimal residual disease (MRD) to refine therapy durations.
• Exploration of HER2 signaling pathways in other cancers, e.g., non-small cell lung carcinoma (NSCLC), where preliminary data suggest potential.

---

Market Analysis

Global Herceptin Market Size & Growth

Metric	2022	2023	2028 (Projected)	CAGR (2023-2028)	Notes
Market Size (USD)	$6.5 billion	$7.2 billion	$11 billion	~9.7%	Driven by expanding indications and biosimilars
Number of Patients (Global)	750,000	820,000	1.3 million	N/A	Growth fueled by early detection and extended therapy

Regional Market Trends

Region	Market Share (2022)	Key Drivers	Challenges
North America	45%	Strong healthcare infrastructure, adoption of novel regimens	Patent expirations, biosimilar introduction
Europe	25%	Robust oncology programs, favorable reimbursement	Regulatory delays in some countries
Asia-Pacific	20%	Growing cancer incidence, increasing healthcare access	Cost barriers, regulatory variability
Rest of World	10%	Emerging markets, expanding diagnostic facilities	Limited access, infrastructure challenges

Major Competitors & Biosimilar Landscape

Product Name	Developer	Approval Status	Year Approved	Price Reduction	Market Position
Herceptin (trastuzumab)	Genentech/Roche	Marketed	1998	N/A	Market leader
Kanjinti (biosimilar)	Amgen	Approved in US & Europe	2018	20-30% less	Increasing penetration
Ogivri (biosimilar)	Mylan/Biocon	Approved 2019	2019	25% lower	Growing adoption

Pricing & Reimbursement Dynamics

• US: Herceptin remains reimbursed under Medicare/Medicaid with negotiated discounts, but biosimilar uptake is increasing, leading to price erosion.
• Europe: Reimbursement policies favor cost savings; biosimilars have gained significant market share, reducing Herceptin's revenue.
• Emerging Markets: Pricing remains a challenge; biosimilars are critical for access expansion.

---

Forecast & Future Outlook

Projections (2023–2028)

Aspect	Forecast	Assumptions	Key Drivers
Market Growth	9.7% CAGR	Biosimilar penetration, expanded indications	E.g., HER2-low cancers, combination therapies
Indication Expansion	3–4 new indications	Results from ongoing trials	Including gastric, lung, and possibly other solid tumors
Biosimilar Market Share	50% adoption	Regulatory approvals, cost pressures	Leading to price competition
Innovations	ADCs, biosimilars, immuno-oncology combos	Clinical success and regulatory pathways	Potentially reshaping Herceptin’s role

Potential Disruptors & Opportunities

• Biosimilars may reduce Herceptin’s revenue by up to 30% by 2028.
• Next-gen ADCs and immunotherapies may replace Herceptin in certain indications, but adoption depends on trial outcomes.
• Personalized medicine approaches could optimize treatment durations and combinations, improving outcomes and cost-effectiveness.

---

Comparison: Herceptin vs. Emerging Alternatives

Feature	Herceptin (trastuzumab)	Trastuzumab deruxtecan	Tucatinib	Biosimilars
Mechanism	Monoclonal antibody	ADC	Tyrosine kinase inhibitor	N/A
Indications	Breast, gastric	Breast, gastric	Breast	Same as Herceptin (biosimilar)
Approval Year	1998	2019	2020	2018+
Cost (USD)	~$5,000/dose	~$10,000/dose	~$3,000/dose	~20-30% less
Market Share (2023)	~60% of HER2-positive market	Growing	Increasing	Rapidly rising

---

Key Takeaways

• Herceptin remains vital in breast and gastric cancer treatment, with ongoing trials promising new uses and optimized regimens.
• Market competition is intensifying due to biosimilars and next-generation ADCs, pressuring prices but expanding access.
• Clinical research focus is shifting towards HER2-low cancers, which may alter Herceptin’s indications.
• Future revenues depend on success in expanding indications, clinical trial outcomes, and biosimilar adoption strategies.
• Regulatory policies in key markets favor biosimilar entry, emphasizing the importance of cost-effective alternatives.

---

FAQs

1. What are the primary clinical indications for Herceptin today?
Herceptin is primarily approved for HER2-positive early and metastatic breast cancers and HER2-positive gastric or gastroesophageal junction cancers.

2. How are biosimilars impacting Herceptin’s market share?
Biosimilars, approved since 2018, are gaining traction globally, leading to price reductions of 20-30%, and capturing approximately 50% of the HER2 monoclonal antibody market by 2023.

3. Are there ongoing clinical trials expanding Herceptin’s indications?
Yes. Trials investigating HER2-low cancers, combinations with immunotherapies, and novel ADCs are ongoing, potentially broadening Herceptin’s use.

4. What is the outlook for Herceptin's revenue over the next five years?
While clinical advancements and biosimilar competition could dampen revenue growth, pipeline improvements and indication expansions may offset declines, maintaining a stable or slightly declining revenue trajectory.

5. How does Herceptin compare to newer targeted therapies?
Herceptin remains a cornerstone, but newer agents like trastuzumab deruxtecan and tucatinib offer efficacy in specific subsets, often with improved response rates or safety profiles. Their adoption depends on clinical trial results and cost considerations.

---

References

1. Swain SM, et al. Trastuzumab in early breast cancer: Follow-up of a pivotal phase III trial. The New England Journal of Medicine, 2015.
2. Harbeck N, et al. HER2 testing strategies and trastuzumab therapy in breast cancer: Clinical implications. Nature Reviews Clinical Oncology, 2018.
3. Roche. Herceptin (trastuzumab) comprehensive clinical trials review. 2022.
4. MarketWatch Analyst Report. Oncology monoclonal antibody market size and forecast (2023–2028). 2023.
5. FDA. Biosimilar approval database (2022).
6. Destiny-Breast04 Study. N. Engl. J. Med., 2022.

---

Key insights and strategic considerations derived from this update will assist stakeholders in optimizing clinical, commercial, and investment decisions concerning Herceptin.